Brind.
  1. Eli Lilly and Company announced agreements to acquire potential targets, filing reports with the SEC.

Eli Lilly acquired Scorpion Therapeutics from Axel Hoos, who previously served as SVP at GSK.

2 reports, 2 independent Updated Sep 3
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Eli Lilly acquired Scorpion Therapeutics from Axel Hoos, who previously served as SVP at GSK.

Who's involved

What this event is mainly about
Axel HoosEli Lilly and Company

Keep exploring

Part of

Eli Lilly and Company announced agreements to acquire potential targets, filing reports with the SEC.

Also in this story

All 3 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAdagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a compa
  • BioPharma DiveVenture firm Frazier closes $1.3B fund for early-stage biotech investing This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPhar